Veracyte (VCYT) EBIT (2012 - 2026)

Veracyte has disclosed EBIT across 15 years of filings, most recently posting $22.6 million for Q1 2026.

• EBIT for Q1 2026 came in at $22.6 million, up 679.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $77.5 million (up 227.06% YoY), and the FY2025 annual result was $57.8 million, up 257.93% from the prior year.
• EBIT came in at $22.6 million for Q1 2026 at Veracyte, down from $37.2 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $37.2 million in Q4 2025 to a low of -$35.5 million in Q4 2023.
• The 5-year median for EBIT is -$5.3 million (2025), against an average of -$1.8 million.
• Across the five-year window, EBIT sank 555.11% in 2023 and soared 790.9% in 2025, its largest moves.
• Veracyte's EBIT stood at -$5.4 million in 2022, then tumbled by 555.11% to -$35.5 million in 2023, then jumped by 111.76% to $4.2 million in 2024, then jumped by 790.9% to $37.2 million in 2025, then sank by 39.12% to $22.6 million in 2026.
• The last three EBIT figures came in at $22.6 million (Q1 2026), $37.2 million (Q4 2025), and $22.9 million (Q3 2025), per Business Quant data.